Abstract
Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Central Nervous System Agents in Medicinal Chemistry
Title:Genetics in Neural Toxicities of Drugs
Volume: 12 Issue: 4
Author(s): Da-Yong Lu, Ting-Ren Lu and Peng-Peng Zhu
Affiliation:
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Abstract: Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren and Zhu Peng-Peng, Genetics in Neural Toxicities of Drugs, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/187152412803760591
DOI https://dx.doi.org/10.2174/187152412803760591 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
CNS & Neurological Disorders - Drug Targets The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?
Current Alzheimer Research Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry Disequilibrium and Risk of Falling in the Elderly is a Priority for Health Services
Reviews on Recent Clinical Trials Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
Current Pharmaceutical Design Editorial [ Pain Guest Editors: Robert W. Gereau IV & Ferdinando Nicoletti ]
Current Neuropharmacology Enhanced Neuroprotection of Ischemic Stroke Based on Liposomal Drug Delivery System Loading a Novel Uncoupler of Ischemia-induced nNOSPSD- 95
Current Signal Transduction Therapy A traditional Chinese Medicine, YXQN, Reduces Amyloid-induced Cytotoxicity by Inhibiting Aβ42 Aggregation and Fibril Formation
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Synthesis, Anticonvulsant and Neurotoxicity Evaluation of Some Newer N-(2-benzoylbenzofuran-3-yl)-3-(substituted)-propanamide Analogs
Central Nervous System Agents in Medicinal Chemistry Role of Ectonucleotidases in Synapse Formation During Brain Development: Physiological and Pathological Implications
Current Neuropharmacology Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction
CNS & Neurological Disorders - Drug Targets Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Current Alzheimer Research Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease: The Overlap Syndrome
Current Respiratory Medicine Reviews